Azithramycine is a lipid of Polyketides (PK) class. Azithramycine is associated with abnormalities such as Respiratory Tract Infections, Pneumonia, Lower respiratory tract infection, Infection and Nonspecific urethritis. The involved functions are known as Lysis, Selection, Genetic, Mutation, Relapse and Adaptation. Azithramycine often locates in Blood, Respiratory System, Genitourinary system, Back and Chest. The associated genes with Azithramycine are Genes, rRNA, Genome, RPL22 gene, OPRM1 gene and tryptic soy broth. The related lipids are Liposomes, Phosphatidylserines, Promega, Lipopolysaccharides and Steroids. The related experimental models are Mouse Model, Knock-out and Tissue Model.
To understand associated biological information of Azithramycine, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.
Azithramycine is suspected in Infection, Pneumonia, Trachoma, Respiratory Tract Infections, Gonorrhea, Infectious disease of lung and other diseases in descending order of the highest number of associated sentences.
Disease | Cross reference | Weighted score | Related literature |
---|
We collected disease MeSH terms mapped to the references associated with Azithramycine
There are no associated biomedical information in the current reference collection.
Associated locations are in red color. Not associated locations are in black.
Location | Cross reference | Weighted score | Related literatures |
---|
Function | Cross reference | Weighted score | Related literatures |
---|
Lipid concept | Cross reference | Weighted score | Related literatures |
---|
Gene | Cross reference | Weighted score | Related literatures |
---|
Mouse Model are used in the study 'Azithromycin increases in vitro fibronectin production through interactions between macrophages and fibroblasts stimulated with Pseudomonas aeruginosa.' (Cory TJ et al., 2013), Mouse Model are used in the study 'Efficacy of azithromycin, clarithromycin and beta-lactam agents against experimentally induced bronchopneumonia caused by Haemophilus influenzae in mice.' (Miyazaki S et al., 2001), Mouse Model are used in the study 'Oral anti-pneumococcal activity and pharmacokinetic profiling of a novel peptide deformylase inhibitor.' (Gross M et al., 2004), Mouse Model are used in the study 'Inhibition of quorum sensing in Pseudomonas aeruginosa by azithromycin and its effectiveness in urinary tract infections.' (Bala A et al., 2011) and Mouse Model are used in the study 'Enhanced efficacy of single-dose versus multi-dose azithromycin regimens in preclinical infection models.' (Girard D et al., 2005).
Knock-out are used in the study 'Influence of rhlR and lasR on Polymyxin Pharmacodynamics in Pseudomonas aeruginosa and Implications for Quorum Sensing Inhibition with Azithromycin.' (Bulman ZP et al., 2017) and Knock-out are used in the study 'Azithromycin in Pseudomonas aeruginosa biofilms: bactericidal activity and selection of nfxB mutants.' (Mulet X et al., 2009).
Tissue Model are used in the study 'Development of a population pharmacokinetic model characterizing the tissue distribution of azithromycin in healthy subjects.' (Zheng S et al., 2014).
Model | Cross reference | Weighted score | Related literatures |
---|
Authors | Title | Published | Journal | PubMed Link |
---|---|---|---|---|
Berg-Candolfi M and Candolfi E | Depression of the N-demethylation of erythromycin, azithromycin, clarithromycin and clindamycin in murine Toxoplasma infection. | 1996 | Int. J. Parasitol. | pmid:9024879 |
Clearance to market azithromycin as prevention for a common OI in advanced AIDS. | 1996 | AIDS Patient Care STDS | pmid:11361535 | |
Segreti J et al. | In vitro activity of macrolides against intracellular Legionella pneumophila. | 1996 | Diagn. Microbiol. Infect. Dis. | pmid:8902407 |
Wondrack L et al. | Clinical strain of Staphylococcus aureus inactivates and causes efflux of macrolides. | 1996 | Antimicrob. Agents Chemother. | pmid:8849266 |
Tabbara KF et al. | Single-dose azithromycin in the treatment of trachoma. A randomized, controlled study. | 1996 | Ophthalmology | pmid:8637698 |
Bertoni G et al. | Triple therapy with azithromycin, omeprazole, and amoxicillin is highly effective in the eradication of Helicobacter pylori: a controlled trial versus omeprazole plus amoxicillin. | 1996 | Am. J. Gastroenterol. | pmid:8607489 |
Hulten K et al. | In-vitro activity of azithromycin in against intracellular Helicobacter pylori. | 1996 | J. Antimicrob. Chemother. | pmid:9182105 |
Di Mario F et al. | Azithromycin for the cure of Helicobacter pylori infection. | 1996 | Am. J. Gastroenterol. | pmid:8607490 |
Na-Bangchang K et al. | Activity of artemether-azithromycin versus artemether-doxycycline in the treatment of multiple drug resistant falciparum malaria. | 1996 | Southeast Asian J. Trop. Med. Public Health | pmid:9185262 |
Ednie LM et al. | Comparative activities of clarithromycin, erythromycin, and azithromycin against penicillin-susceptible and penicillin-resistant pneumococci. | 1996 | Antimicrob. Agents Chemother. | pmid:8843313 |
Carbon C et al. | Economic analysis of antibiotic regimens used in the treatment pharyngitis: a prospective comparison of azithromycin versus roxithromycin. | 1996 | J. Antimicrob. Chemother. | pmid:8818856 |
Gerbaux C et al. | Hyperactivity of cathepsin B and other lysosomal enzymes in fibroblasts exposed to azithromycin, a dicationic macrolide antibiotic with exceptional tissue accumulation. | 1996 | FEBS Lett. | pmid:8830663 |
Domingo S and Gamazo C | Inadequate azithromycin activity against Brucella melitensis in mice with acute or chronic infections. | 1996 | J Chemother | pmid:8835110 |
Conte JE et al. | Single-dose intrapulmonary pharmacokinetics of azithromycin, clarithromycin, ciprofloxacin, and cefuroxime in volunteer subjects. | 1996 | Antimicrob. Agents Chemother. | pmid:8807050 |
Nash KA and Inderlied CB | Rapid detection of mutations associated with macrolide resistance in Mycobacterium avium complex. | 1996 | Antimicrob. Agents Chemother. | pmid:8807078 |
Dupont C et al. | Microbiological findings about pulmonary cryptosporidiosis in two AIDS patients. | 1996 | J. Clin. Microbiol. | pmid:8748314 |
Xu G et al. | Effect of macrolide antibiotics on macrophage functions. | 1996 | Microbiol. Immunol. | pmid:8865152 |
Wildfeuer A et al. | Uptake of azithromycin by various cells and its intracellular activity under in vivo conditions. | 1996 | Antimicrob. Agents Chemother. | pmid:8787883 |
Meloni G and Meloni T | Azithromycin vs. doxycycline for Mediterranean spotted fever. | 1996 | Pediatr. Infect. Dis. J. | pmid:8933556 |
Jackson MA et al. | Breakthrough sepsis in macrolide-resistant pneumococcal infection. | 1996 | Pediatr. Infect. Dis. J. | pmid:8933560 |
Hicks P et al. | Azithromycin therapy for Cryptosporidium parvum infection in four children infected with human immunodeficiency virus. | 1996 | J. Pediatr. | pmid:8765631 |
Tateda K et al. | Direct evidence for antipseudomonal activity of macrolides: exposure-dependent bactericidal activity and inhibition of protein synthesis by erythromycin, clarithromycin, and azithromycin. | 1996 | Antimicrob. Agents Chemother. | pmid:8891128 |
Wintermeyer SM et al. | Dirithromycin: a new macrolide. | 1996 | Ann Pharmacother | pmid:8893122 |
Akita H et al. | [Bacteriological, pharmacokinetic and clinical evaluation of azithromycin in the pediatric field]. | 1996 | Jpn J Antibiot | pmid:8986553 |
Nishimura T et al. | [Clinical evaluation of azithromycin in pediatric infections]. | 1996 | Jpn J Antibiot | pmid:8986554 |
Haruta T and Kobayashi Y | [Therapeutic efficacy of azithromycin in pediatrics]. | 1996 | Jpn J Antibiot | pmid:8986555 |
Havlir DV et al. | Prophylaxis against disseminated Mycobacterium avium complex with weekly azithromycin, daily rifabutin, or both. California Collaborative Treatment Group. | 1996 | N. Engl. J. Med. | pmid:8676932 |
Tursi A et al. | The use of azithromycin in short-term low-dose triple therapies for Helicobacter pylori infection. | 1996 | Am. J. Gastroenterol. | pmid:8677967 |
Thorpe EM et al. | Chlamydial cervicitis and urethritis: single dose treatment compared with doxycycline for seven days in community based practises. | 1996 | Genitourin Med | pmid:8698374 |
Pacifico L et al. | Comparative efficacy and safety of 3-day azithromycin and 10-day penicillin V treatment of group A beta-hemolytic streptococcal pharyngitis in children. | 1996 | Antimicrob. Agents Chemother. | pmid:8849215 |
Wilton LV et al. | A comparison of ciprofloxacin, norfloxacin, ofloxacin, azithromycin and cefixime examined by observational cohort studies. | 1996 | Br J Clin Pharmacol | pmid:8730972 |
Jaruratanasirikul S et al. | Distribution of azithromycin into brain tissue, cerebrospinal fluid, and aqueous humor of the eye. | 1996 | Antimicrob. Agents Chemother. | pmid:8851625 |
Bedos JP and Veber B | [Lower respiratory infections: predictive factors of therapeutic response]. | 1996 | Rev Pneumol Clin | pmid:9033917 |
Zuck P | [Efficacy of a 5-day treatment with an azalide (azithromycin) in superinfections of chronic bronchitis]. | 1996 | Rev Pneumol Clin | pmid:9033919 |
Hayle R et al. | Efficacy and safety of azithromycin versus phenoxymethylpenicillin in the treatment of acute maxillary sinusitis. | 1996 | Eur. J. Clin. Microbiol. Infect. Dis. | pmid:8997555 |
Adhikari P et al. | Evaluation of safety and efficacy of azithromycin in lower respiratory tract infections (LRTI) | 1996 | Indian J Med Sci | pmid:9057364 |
Three new studies expand understanding of MAC therapy. | 1996 | Am J Health Syst Pharm | pmid:8899122 | |
Cellesi C et al. | Susceptibility of macrolide and beta-lactam antibiotics of Streptococcus pyogenes strains isolated over a four-year period in central Italy. | 1996 | J Chemother | pmid:8808714 |
Gnarpe J et al. | In vitro activities of azithromycin and doxycycline against 15 isolates of Chlamydia pneumoniae. | 1996 | Antimicrob. Agents Chemother. | pmid:8843291 |
Welsh L et al. | In vitro activities of azithromycin, clarithromycin, erythromycin, and tetracycline against 13 strains of Chlamydia pneumoniae. | 1996 | Antimicrob. Agents Chemother. | pmid:8787907 |
Mehaffey PC et al. | Evaluation of in vitro spectra of activity of azithromycin, clarithromycin, and erythromycin tested against strains of Neisseria gonorrhoeae by reference agar dilution, disk diffusion, and Etest methods. | 1996 | J. Clin. Microbiol. | pmid:8789046 |
Keysary A et al. | The in-vitro anti-rickettsial activity of macrolides. | 1996 | J. Antimicrob. Chemother. | pmid:8937968 |
Mein J et al. | Donovanosis: sequelae of severe disease and successful azithromycin treatment. | 1996 | Int J STD AIDS | pmid:8940677 |
Hoque S et al. | Rhodococcus equi in CAPD-associated peritonitis treated with azithromycin. | 1996 | Nephrol. Dial. Transplant. | pmid:8941608 |
Wiselka MJ et al. | Response to oral and intravenous azithromycin in a patient with toxoplasma encephalitis and AIDS. | 1996 | J. Infect. | pmid:8945715 |
Gómez E et al. | Interaction between azithromycin and cyclosporin? | 1996 | Nephron | pmid:8856287 |
Delmée M et al. | In vitro susceptibilities of 180 clinical isolates of Haemophilus influenzae to ampicillin, amoxycillin/clavulanate, cefaclor, cefuroxime, cefotaxime, clarithromycin, and azithromycin. | 1996 | Acta Clin Belg | pmid:8858889 |
Watt B et al. | Comparative activity of azithromycin against clinical isolates of mycobacteria. | 1996 | J. Antimicrob. Chemother. | pmid:8889727 |
Mashkilleyson AL et al. | Treatment of syphilis with azithromycin. | 1996 | Int J STD AIDS | pmid:8652720 |
Patel KB et al. | Comparison of bronchopulmonary pharmacokinetics of clarithromycin and azithromycin. | 1996 | Antimicrob. Agents Chemother. | pmid:8891147 |